Inflammation as a marker for the prediction of internal carotid artery restenosis following eversion endarterectomy-evidence from clinical studies

Angiology

Volumn 62, Issue 7, 2011, Pages 535-542

  Tanaskovic, Slobodan ^a   Isenovic, Esma R ^b   Radak, Djordje ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

C3 complement; carotid endarterectomy; high sensitive C reactive protein; internal carotid artery restenosis

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; COMPLEMENT COMPONENT C3; CYTOKINE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN;

ACUTE CORONARY SYNDROME; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CORONARY STENT; DISEASE MARKER; GENETIC POLYMORPHISM; GENOTYPE; HEART PROTECTION; HUMAN; INTERNAL CAROTID ARTEY RESTENOSIS; MACROPHAGE; PROGNOSIS; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; VASCULITIS;

C-REACTIVE PROTEIN; CAROTID ARTERY, INTERNAL; CAROTID STENOSIS; COMPLEMENT C3; ENDARTERECTOMY, CAROTID; HUMANS; INFLAMMATION; PREDICTIVE VALUE OF TESTS; RECURRENCE;

EID: 80054734433     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319710398010     Document Type: Article

References (96)

1. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses. 2004 ; 62 (4). 499-506
2. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999 ; 138 (5 pt 2). S419 - S420
3. Dósa E, Rugonfalvi-Kiss S, Prohászka Z, et al. Marked decrease in the levels of two inflammatory markers, hs-C-reactive protein and fibrinogen in patients with severe carotid atherosclerosis after eversion carotid endarterectomy. Inflamm Res. 2004 ; 53 (11). 631-635 (Pubitemid 40385322)
4. Libby P. Inflammation in atherosclerosis. Nature. 2002 ; 420 (6917). 868-874 (Pubitemid 36019640)
5. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003 ; 108 (17). 2054-2059 (Pubitemid 37337577)
6. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002 ; 347 (20). 1557-1565 (Pubitemid 35315836)
7. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 ; 342 (20). 836-843 (Pubitemid 30165206)
8. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003 ; 107 (3). 363-369 (Pubitemid 36158034)
9. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002 ; 105 (16). 1890-1896 (Pubitemid 34437614)
10. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002 ; 106 (8). 913-919 (Pubitemid 34925323)
11. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001 ; 103 (21). 2531-2534 (Pubitemid 32521959)
12. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000 ; 102 (18). 2165-2168
13. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low-density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001 ; 103 (9). 1194-1197 (Pubitemid 32221339)
14. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003 ; 107 (13). 1783-1790 (Pubitemid 36418360)
15. Verma S, Li SH, Wang CH, et al. Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. J Mol Cell Cardiol. 2003 ; 35 (4). 417-419 (Pubitemid 36411703)
16. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004 ; 109 (17). 2058-2067 (Pubitemid 38620212)
17. Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003 ; 107 (3). 370-371
18. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002 ; 106 (12). 1439-1441
19. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003 ; 107 (3). 398-404
20. Liuzzo G, Biasucci LM, Rebuzzi AG, Gallimore JR, Lanza AG, Quaranta G. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation. 1996 ; 94 (10). 2373-2380 (Pubitemid 26403561)
21. Paraskevas KI, Bessias N, Papas TT, Andrikopoulos V, Mikhailidis DP. Is high-sensitivity C-reactive protein associated with subclinical peripheral atherosclerosis?. Angiology. 2009 ; 60 (1). 8-11
22. Paraskevas KI, Mikhailidis DP, Veith FJ. Mechanisms to explain the poor results of carotid artery stenting (CAS) in symptomatic patients to date and options to improve CAS outcomes. J Vasc Surg. 2010 ; 52 (5). 1367-1375
23. NASCET Investigators. Clinical alert: benefit of carotid endarterectomy for patients with high-grade stenosis of the internal carotid artery. National Institute of Neurological Disorders and Stroke, Stroke and Trauma Division. North American Symptomatic Carotid Endarterectomy Trial. Stroke. 1991 ; 22 (6). 816-817
24. Liapis CD, Bell PF, Mikhailidis DP, et al. ESVS Guidelines Collaborators; European Society for Vascular Surgery. ESVS Guidelines: Section A-prevention in patients with carotid stenosis. Curr Vasc Pharmacol. 2010 ; 8 (5). 673-681
25. Schillinger M, Exner M, Mlekusch W, et al. Acute-phase response after stent implantation in the carotid artery: association with 6-month in-stent restenosis. Radiology. 2003 ; 227 (2). 516-521 (Pubitemid 36514771)
26. Szmitko PE, Wang C-H, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation Part I. Circulation. 2003 ; 108 (16). 1917-1923 (Pubitemid 37296533)
27. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J. 2000 ; 21 (14). 1152-1158 (Pubitemid 30438640)
28. Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ. The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb Haemost. 1995 ; 74 (1). 552-559
29. Ridker PM, Cushman M, Stampfer MJ, Tracy RP. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 ; 336 (14). 973-979 (Pubitemid 27152782)
30. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable patients. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997 ; 349 (9050). 462-466 (Pubitemid 27077826)
31. Toss H, Lindhal B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. Circulation. 1997 ; 96 (12). 4204-4210 (Pubitemid 28007445)
32. Doggen CJM, Berckmans RJ, Sturk A, Manger V, Rosendaal FR. C-reactive protein, cardiovascular risk factors and the association with myocardial infarction in men. J Intern Med. 2000 ; 248 (5). 406-414
33. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998 ; 97 (5). 425-428 (Pubitemid 28090212)
34. Van Exel E, Gusseklov J, de Craen AJM, Bootsma van der Wiel A, Frolich M, Westendorp RGJ. Inflammation and stroke: the Leiden 85-Plus Study. Stroke. 2002 ; 33 (4). 1135-1138 (Pubitemid 34293603)
35. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001 ; 32 (1). 133-138 (Pubitemid 32063837)
36. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke. 1999 ; 30 (5). 981-985 (Pubitemid 29211614)
37. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001 ; 89 (9). 763-771 (Pubitemid 34633846)
38. Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003 ; 107 (3). 370-371
39. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 ; 107 (3). 499-511 (Pubitemid 36158056)
40. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999 ; 34 (5). 1512-1521 (Pubitemid 29528666)
41. Angioi M, Abdelmouttaleb I, Rodriguez RM, et al. Increased C-reactive protein levels in patients with in-stent restenosis and its implications. Am J Cardiol. 2001 ; 87 (10). 1189-1193 (Pubitemid 32453241)
42. Dibra A, Mehilli J, Braun S, et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med. 2003 ; 114 (9). 715-722 (Pubitemid 36776352)
43. de Winter RJ, Koch KT, van Straalen JP, et al. C-reactive protein and coronary events following percutaneous coronary angioplasty. Am J Med. 2003 ; 115 (2). 85-90 (Pubitemid 37288834)
44. Anderson JL, Muhlestein JB. Restenosis after coronary intervention: narrowing C-reactive protein's prognostic potential?. Am J Med. 2003 ; 115 (2). 147-149 (Pubitemid 37288844)
45. Otsuka M, Hayashi Y, Ueda H, Imazu M, Kohno N. Predictive value of preprocedural fibrinogen concerning coronary stenting. Atherosclerosis. 2002 ; 164 (2). 371-378 (Pubitemid 35223089)
46. Van Der Meer I, de Maat MP, Hak AE, et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke. 2002 ; 33 (12). 2750-2755 (Pubitemid 35462838)
47. Alvarez Garcia B, Ruiz C, Chacon P, Sabin JA, Matas M. High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. J Vasc Surg. 2003 ; 38 (5). 1018-1024 (Pubitemid 37409637)
48. Hunter GC. Edgar J, Poth Memorial/WL Gore and Associates, Inc. Lectureship. The clinical and pathological spectrum of recurrent carotid stenosis. Am J Surg. 1997 ; 174 (6). 583-588
49. Frericks H, Kievit J, van Baalen JM, van Bockel JH. Carotid recurrent stenosis and risk of ipsilateral stroke: a systematic review of the literature. Stroke. 1998 ; 29 (1). 244-250 (Pubitemid 28046971)
50. Zierler RE, Bandyk DF, Thiele BL, Strandness DE. Carotid artery stenosis following endarterectomy. Arch Surg. 1982 ; 117 (11). 1408-1415 (Pubitemid 13229668)
51. Ricotta JJ, O'Brien MS, DeWeese JA. Natural history of recurrent and residual stenosis after carotid endarterectomy: implications for postoperative surveillance and surgical management. Surgery. 1992 ; 112 (4). 656-661
52. Trisal V, Paulson T, Hans SS, Mittal V. Carotid artery restenosis: an ongoing disease process. Am Surg. 2002 ; 68 (3). 275-279 (Pubitemid 44943194)
53. Rugonfalvi-Kiss S, Dósa E, Madsen HO, et al. High rate of early restenosis after carotid eversion endarterectomy in homozygous carriers of the normal mannose-binding lectin genotype. Stroke. 2005 ; 36 (5). 944-948 (Pubitemid 40629281)
54. Széplaki G, Varga L, Laki J, et al. Elevated complement C3 is associated with early restenosis after eversion carotid endarterectomy. Thromb Haemost. 2006 ; 96 (4). 529-534 (Pubitemid 44560690)
55. Telman G, Kouperberg E, Hlebtovsky A, et al. Embolic potential and ultrasonic characteristics of plaques in patients with severe unilateral carotid restenosis more than one year after surgery. J Neur Sci. 2009 ; 285 (1-2). 85-87
56. Makihara N, Tozoda K, Uda K, et al. Characteristic sonoraphic findings of early restenosis after carotid endarterectomy. J Ultrasound Med. 2008 ; 27 (9). 1345-1352
57. Malek A, Malek AK, Leszczynski J, et al. Carotid clamping time as a risk factor for early restenosis after carotid endarterectomy. Eur J Vasc Endovasc Surg. 2005 ; 30 (2). 143-146 (Pubitemid 40932012)
58. Hellings WE, Moll FL, De Vries JP, Ackerstaff RG, Seldenrijk KA, Met R. Atherosclerotic plaque composition and occurrence of restenosis after carotid endarterectomy. J Vasc Surg. 2008 ; 299 (5). 547-554 (Pubitemid 351214252)
59. Paraskevas KI, Mikhailidis DP, Liapis CD. Internal carotid artery occlusion: association with atherosclerotic disease in other arterial beds and vascular risk factors. Angiology. 2007 ; 58 (3). 329-335 (Pubitemid 46956253)
60. Balk EM, Lau J, Goudas LC, et al. Effects of statin non-lipid serum markers associated with cardiovascular disease. Ann Intern Med. 2003 ; 139 (8). 670-682 (Pubitemid 38124539)
61. Nagila A, Permpongpaiboon T, Tantrarongroj S, et al. Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep. 2009 ; 61 (5). 892-898
62. Kassan M, Montero MJ, Sevilla MA. In vitro antioxidant activity of pravastatin provides vascular protection. Eur J Pharmacol. 2010 ; 630 (1-3). 107-111
63. Tsimihodimos V, Kostoula A, Kakafika A, et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther. 2004 ; 9 (1). 27-33 (Pubitemid 38525755)
64. Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab. 2010 ; 95 (2). 829-836
65. Tziomalos K, Kakafika AI, Athyros VG, Karagiannis A, Mikhailidis DP. The role of statins for the primary and secondary prevention of coronary heart disease in women. Curr Pharm Des. 2009 ; 15 (10). 1054-1062
66. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des. 2009 ; 15 (5). 479-489
67. Paraskevas KI, Stathopoulos V, Mikhailidis DP. Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol. 2008 ; 6 (4). 237-239
68. Koutouzis M, Paraskevas KI, Rallidis LS, et al. Statin treatment, carotid atherosclerotic plaque macrophage Infiltration and circulating inflammatory markers. Open Cardiovasc Med J. 2008 ; 2: 110-114
69. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999 ; 100 (3). 230-235 (Pubitemid 29340127)
70. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin and the risk of coronary events after mzocardial infacrtion in patients with average cholesterol levels. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998 ; 98 (9). 839-844 (Pubitemid 28397432)
71. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359 (21). 2195-2207
72. Hlatky M. Expanding the orbit of primary prevention-moving beyond JUPITER [editorial]. N Engl J Med. 2008 ; 359 (21). 2280-2282
73. Zacho J, Tybjærg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008 ; 359 (18). 1897-1908
74. Breimer LH, Mikhailidis DP. Primary prevention using statins: to be or not to be?. Curr Med Res Opin. 2010 ; 26 (11). 2701-2706
75. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996 ; 348 (9038). 1329-1339
76. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 2001 ; 88 (6). 672-674 (Pubitemid 32831103)
77. Iijima R, Byrne RA, Ndrepepa G, et al. Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. Heart. 2009 ; 95 (2). 107-112
78. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999 ; 100 (3). 230-235 (Pubitemid 29340127)
79. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. J Am Med Assoc. 2001 ; 286 (1). 64-70 (Pubitemid 32606333)
80. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001 ; 103 (9). 1191-1193 (Pubitemid 32221338)
81. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003 ; 23 (12). 2131-2137 (Pubitemid 37532311)
82. Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost. 2003 ; 1 (9). 1897-1905
83. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999 ; 100 (8). 793-798 (Pubitemid 29398875)
84. Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther. 2003 ; 73 (3). 232-241 (Pubitemid 36269674)
85. Vavuranakis M, Latsios G, Aggelis D, et al. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Clin Ther. 2006 ; 28 (6). 860-871 (Pubitemid 44081951)
86. Quinn MJ, Bhatt DL, Zidar F, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2004 ; 93 (6). 679-684 (Pubitemid 38338553)
87. Kreutz RP, Tantry US, Bliden KP, Gurbel PA. Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists. Blood Coagul Fibrinolysis. 2007 ; 18 (8). 713-718 (Pubitemid 350059328)
88. Modica A, Karlsson F, Mooe T. Platelet aggregation and aspirin nonresponsiveness increase when an acute coronary syndrome is complicated by an infection. J Thromb Haemost. 2007 ; 5 (3). 507-511 (Pubitemid 46680683)
89. Canavan B, Salem RO, Schurgin S, et al. Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. J Clin Endocrinol Metab. 2005 ; 90 (10). 5779-5785 (Pubitemid 41415492)
90. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 ; 360 (4). 363-375
91. Radak DJ, Ilijevski NS, Nenezic D, et al. Temporal trends in eversion carotid endarterectomy for carotid atherosclerosis: single-center experience with 5,034 patients. Vascular. 2007 ; 15 (4). 205-210 (Pubitemid 47605368)
92. Radak D, Tanaskovic S, Ilijevski N, et al. Eversion carotid endarterectomy versus best medical treatment in symptomatic patients with near total internal carotid occlusion: a prospective nonrandomized trial. Ann Vasc Surg. 2009 ; 24 (2). 185-189
93. Radak D, Davidovic L, Vukobratov V, et al. Carotid artery aneurysms: serbian multicentric study. Ann Vasc Surg. 2007 ; 21 (1). 23-29 (Pubitemid 46237762)
94. Ilijevski N, Gajin P, Neskovic V, Kolar J, Radak D. Postendarterectomy common carotid artery pseudoaneurysm. Vascular. 2006 ; 14 (3). 177-180 (Pubitemid 44701083)
95. Ilijevski N, Krivokapic B, Smiljanic B, et al. Carotid endarterectomy in cervical block anesthesia in patients with occluded contralateral internal carotid artery. Srp arh celok lek. 2006 ; 134 (3-4). 122-128
96. Radak D, Radevic B, Sternic N, et al. Single center experience on eversion versus standard carotid endarterectomy: a prospective non-randomized study. Cardiovasc Surg. 2000 ; 8 (6). 422-428